Pfizer India (PFIZER) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
28 Jul, 2026Executive summary
Unaudited financial results for the quarter ended June 30, 2026, were approved by the Board on July 28, 2026.
Financial statements prepared in accordance with Ind AS and SEBI regulations.
Limited review by statutory auditors found no modifications or material misstatements.
Financial highlights
Revenue from operations for Q1 FY27 was ₹653.17 crore, up from ₹603.05 crore in Q1 FY26.
Total income for the quarter was ₹698.01 crore, compared to ₹670.22 crore in Q4 FY26 and ₹670.22 crore in Q1 FY26.
Net profit for the quarter was ₹204.47 crore, compared to ₹191.75 crore in Q1 FY26.
Earnings per share (EPS) for the quarter was ₹44.69, up from ₹41.91 in Q1 FY26.
Outlook and guidance
The company continues to monitor the impact of the New Labour Codes and will account for any changes as per applicable standards.
Latest events from Pfizer India
- FY26 revenue rose, net profit reached ₹722.43 crore, and a ₹75/share dividend is proposed.PFIZER
Q4 25/26 - Net profit increased to ₹189.02 crore in Q3 FY26, with stable revenue and notable exceptional costs.PFIZERQ3 25/26
- Strong revenue and profit growth, with major dividends paid after asset sale gains.PFIZERQ2 25/26
- Strong financials, special dividend, and new launches mark a milestone 75th year.PFIZERAGM 2025
- Despite a tough year, strong brand growth and new launches signal a return to positive momentum.PFIZERAGM 2024
- Revenue and profit rose year-over-year, with strong operations and pending asset sale.PFIZERQ2 24/25
- Net profit and EPS increased year-over-year, with strong revenue growth and no audit issues.PFIZERQ1 24/25
- Revenue and profit increased year-over-year, with Thane property sale awaiting approval.PFIZERQ3 24/25
- FY25 net profit surged to Rs. 767.60 crore; Rs. 165/share total dividend recommended.PFIZERQ4 24/25